News Articles and Montana BioScience Alliance Newsletters
The new, three-year project aims at improving access throughout Montana to often life-saving treatments available through clinical trials. Funded with nearly $750,000 from biotechnology company Genentech through a grant aimed at advancing equitable access to health care, the project seeks to optimize portions of Billings Clinic’s electronic health record systems for clinical trials and engage underserved communities to let more people in the state receive clinical trial care.
MSU will host a free one-day workshop for biotechnology entrepreneurs and others interested in business ventures involving the life-sciences. The event will present practical information about starting a company, securing intellectual property, fundraising and licensing technology. The event is co-sponsored by the Montana Bioscience Alliance and the Montana Innovation Partnership.
Awards will be offered by the National Institutes of Health and will be linked to grants currently held by the Institute of Translational Health Services and are open to: (1) students enrolled in doctoral programs at institutions of higher education in Washington, Wyoming, Alaska, Montana, and Idaho meeting T32/TL1 eligibility criteria, who can request 2 to 3 years of support for stipend and tuition, and (2) early career faculty and postdoctoral investigators meeting KL2 eligibility criteria, who can request support for 3 […]
Gaize, Inc. has announced the launch of their impairment screening solution for cannabis and other drugs. The product is a first-of-its-kind fully automated, non-invasive and portable eye movement test. It’s an objective way to detect the involuntary eye movement changes associated with impairment. Gaize recently completed the world’s largest cannabis impairment clinical trial, which validated the effectiveness of the product.
Alercell has launched a new website—Lena Diagnostics, www.lenadx.com—dedicated to proprietary tests focused on early detection of cancer and leukemia.
As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.
Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR
Contract Pre-solicitation for R&D that will contribute toward ARPA-H mission needs and SBIR program objectives.
Updates from product development and small business programs
The wait is finally over as the Biotechnology Innovation Organization (BIO) taps John F. Crowley, a longtime leader and tireless patient advocate in the biotech industry, to fill the role of the organization’s new CEO.